Advertisement

Rheumaderm pp 289-293 | Cite as

Enalapril (10 Mg/Day) in Systemic Sclerosis

One Year, Double Blind, Randomised Study (ESS-1): Pulmonary Substudy—Effects of Three Month Treatment
  • St. OstrowskiEmail author
  • M. Chibowska
  • A. Bilan
  • R. Palusiński
  • J. Węglarz
  • B. Makaruk
  • D. Krasowska
  • J. Hanzlik
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)

Abstract

The ESS-1 study is designed to evaluate the long-term effects of enalapril on cardiopulmonary system of patients with systemic sclerosis (SSc). During the one year study period 5 visits are scheduled at 3 month intervals. The effect of 3 months treatment with enalapril (10 mg per day) on lung function was studied in 18 patients with SSc (enalapril group) and compared with controls—23 patients with Ssc (placebo group), mean age, SSc duration, gender and % of patients with dcSSc did not differ significantly in both groups. We performed body plethysmography for total airways resistance (Rtot), and static lung volumes (TLC, ITGV and RV), spirometry for FEV, and FVC and we measured flow parameters (PEF, FEF). We compared initial lung function (first examination) with results after 3 months treatment (second examination) in the enalapril and in the placebo group. Mean values of Rtot, ITGV and RV did not differ significantly in the enalapril group or in the placebo group before and after treatment but FVC, FEV1 and FEF50 were significantly lower in the enalapril group and did not change in the placebo group after three months. We conclude that 3 month treatment with enalapril worsens spirometry of SSc patients. We did not observe any changes in lung functions in the control group in the same three month period.

Keywords

Lung Function Interstitial Lung Disease Systemic Sclerosis American Rheumatism Association Ventilatory Defect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Clop CR, Riker J, Wiliams MH. Serial changes in scleroderma and idiopathic interstitial lung disease. Arch Intern Med. 132: 506–515 (1973).CrossRefGoogle Scholar
  2. 2.
    Medsger TA jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic asclerosis (scleroderma) A life table analysis of clinical and demographic factors in 309 patients. Ann Intern Med, 75: 369–376(1971)PubMedGoogle Scholar
  3. 3.
    Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zukner. Heart disease in systemic Sclerosis. Semin Arthritis Rheum 19: 191–200(1989).PubMedCrossRefGoogle Scholar
  4. 4.
    Subcommittee for scleroderma of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 23:581–590 (1980)CrossRefGoogle Scholar
  5. 5.
    Quanjer PH. Tammeling GJ. Cotes JE. Pedersen OF. Peslin R. Yernault JC. Volumes pulmonaires et debits ventilatoires forces. Groupe de travail sur la standardisation des epreuves fonctionnelles respiratoires. Communaute Europeenne du Charbon et de l’Acier. Position officielle de l’European Respiratory Society. Revue des Maladies Respiratoires. 11 Suppl 3:5–40 (1994).Google Scholar
  6. 6.
    Ulmer WT, Reichel G, Nolte D. Die Lungfunction. Physiologie. Methodik. G. Thieme Verlag. Stuttgard. 1976Google Scholar
  7. 7.
    Silver RM. Interstitial lung disease of systemic sclerosis. International Review of Immunology. 12: 281–291 (1995)CrossRefGoogle Scholar
  8. 8.
    Kane GC, Varga J, Connant EF, Spirn PW, Jimenez S, Fish JE. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respiratory medicine. 90: 223–30 (1996).PubMedCrossRefGoogle Scholar
  9. 9.
    Jacobsen S, Halberg P, Ullman S, Hoier-Madsen M, Petersen J, Mortensen J, Wiik A. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin.Rheumatol. 16: 384–390 (1997).PubMedCrossRefGoogle Scholar
  10. 10.
    Schneider PD, Wiese RA, Hochberg MC, Wigley FM: Serial pulmonary Function in Systemic Sclerosis. Am. J.Med. 73: 385–394 (1982).PubMedCrossRefGoogle Scholar
  11. 11.
    Guttadauria M, Ellman H, Emmanuel G, Kaplan D, Diamond H. Pulmonary function in scleroderma. Arthritis Rheum. 20: 1971–1979 (1997).Google Scholar
  12. 12.
    Spagnolatti L, Zoia MC, Volpini E, Convertino G, Fulgoni P, Corsico A, Vitulo P, Cerveri I. Pulmonary function in patients with systemic sclerosis. Monaldi Arch. Chest Dis. 52: 4–8. (1997)PubMedGoogle Scholar
  13. 13.
    Lofdahl CG. Antihypertensive drugs and airway function, with special reference to calcium channel blockade. J. Cardiovas. Pharmacol 14 Suppl 10: S40–51 (1989)Google Scholar
  14. 14.
    Pelouch V, Kolar F, Ostdal B, Milerova M, Cihak R, Widimsky J: Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: effect of enalapril. Cardiovascular Drugs and Therapy. 11(2); 177–185 (1997).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • St. Ostrowski
    • 1
    Email author
  • M. Chibowska
    • 2
  • A. Bilan
    • 1
  • R. Palusiński
    • 1
  • J. Węglarz
    • 1
  • B. Makaruk
    • 1
  • D. Krasowska
    • 2
  • J. Hanzlik
    • 1
  1. 1.I Department of MedicineLublin University School of MedicineLublinPoland
  2. 2.Department of DermatologyLublin University School of MedicineLublinPoland

Personalised recommendations